Charles River Laboratories International (CRL) Consolidated Net Income (2009 - 2026)

Charles River Laboratories International's Consolidated Net Income history runs 16 years deep, the most recent figure standing at -$276.3 million for Q4 2025.

• In Q4 2025, Consolidated Net Income fell 29.26% year-over-year to -$276.3 million; the TTM figure through Dec 2025 stood at -$142.2 million (down 662.11% YoY), while the FY2025 annual figure was -$142.2 million, down 662.11% from the prior year.
• Consolidated Net Income for Q4 2025 stood at -$276.3 million, down from $55.6 million in the prior quarter.
• The five-year high for Consolidated Net Income was $189.1 million in Q4 2022, with the low at -$276.3 million in Q4 2025.
• The 5-year median for Consolidated Net Income is $92.1 million (2021), against an average of $62.7 million.
• The sharpest annual moves came in 2022 and 2024: Consolidated Net Income jumped 48.94% in 2022, then tumbled 213.12% in 2024.
• Charles River Laboratories International's Consolidated Net Income stood at $139.8 million in 2021, then jumped by 35.24% to $189.1 million in 2022, then retreated by 0.08% to $189.0 million in 2023, then sank by 213.12% to -$213.7 million in 2024, then retreated by 29.26% to -$276.3 million in 2025.
• Business Quant data shows CRL's Consolidated Net Income at -$276.3 million in Q4 2025, $55.6 million in Q3 2025, and $52.7 million in Q2 2025.